CVS Health Corporation (CVS) research: valuation against peers, fundamentals over time, risk and news coverage
CVS
CVS Health CorporationNo data in this window.
Every report in our own archive tagged with this symbol, newest first — fetched from the archive alongside the market data.
Nothing filed on CVS yet. Search the archive for related coverage.
Full archive search for CVSEvery figure on this page is fetched and computed in your browser from free public sources — end-of-day prices and reported financials from Yahoo Finance's open endpoints, and our own archive for the coverage panel. Fundamental history on the free tier runs about four fiscal years and five quarters. Data is best-effort and unaudited; this is market research, not investment advice.
Only 4 resolved forecasts on record — below the 6-period threshold, so no verdict is published.
n = 4 resolved forecasts · Q3 FY2024 to FY 2025 · 4 still outstanding
Insufficient sample — no verdict published. CVS has 4 resolved forecasts on record, below the 6 needed before we will characterise a management team’s forecasting. The record below is published in full; the company is excluded from every ranking on this site until it clears the threshold.
Next report expected 28 Oct 2026 (Q3 FY2026) — Estimated from the issuer's own filing history: FY2025Q3 results were released on 2025-10-29. source
| Period | Measure | Guided | Issued | Reported | Landed | Deviation | Verdict | Sources |
|---|---|---|---|---|---|---|---|---|
| FY 2026revised | EPS (adj.) | $7.90–$8.10 | 2026-08-05 | — | — | — | PENDING | guidance |
| “Adjusted EPS guidance range to $7.90 to $8.10 from $7.30 to $7.50” | ||||||||
| FY 2026revised | EPS | $6.84–$7.04 | 2026-08-05 | — | — | — | PENDING | guidance |
| “GAAP diluted EPS guidance range to $6.84 to $7.04 from $6.24 to $6.44” | ||||||||
| FY 2026revised | EPS (adj.) | $7.30–$7.50 | 2026-05-06 | — | — | — | PENDING | guidance |
| “Adjusted EPS guidance range to $7.30 to $7.50 from $7.00 to $7.20” | ||||||||
| FY 2026revised | EPS | $6.24–$6.44 | 2026-05-06 | — | — | — | PENDING | guidance |
| “GAAP diluted EPS guidance range to $6.24 to $6.44 from $5.94 to $6.14” | ||||||||
| FY 2026 | EPS (adj.) | $7.00–$7.20 | 2026-02-10 | — | — | — | PENDING | guidance |
| “Confirmed Adjusted EPS guidance range of $7.00 to $7.20” | ||||||||
| FY 2026 | EPS | $5.94–$6.14 | 2026-02-10 | — | — | — | PENDING | guidance |
| “Confirmed GAAP diluted EPS guidance range of $5.94 to $6.14” | ||||||||
| FY 2025revised | EPS (adj.) | $6.55–$6.65 | 2025-10-29 | $6.75 | +1.5% | ABOVE | guidance · result | |
| “Raised Adjusted EPS guidance range to $6.55 to $6.65 from $6.30 to $6.40” | ||||||||
| FY 2025revised | EPS | −$0.34 to −$0.24 | 2025-10-29 | $1.39 | +562.1% | ABOVE | guidance · result | |
| “Updated GAAP diluted earnings (loss) per share guidance range to $(0.34) to $(0.24) from $3.84 to $3.94” | ||||||||
| FY 2025revised | EPS (adj.) | $6.30–$6.40 | 2025-07-31 | $6.75 | +5.5% | ABOVE | guidance · result | |
| “Raised Adjusted EPS guidance range to $6.30 to $6.40 from $6.00 to $6.20” | ||||||||
| FY 2025revised | EPS | $3.84–$3.94 | 2025-07-31 | $1.39 | −63.0% | BELOW | guidance · result | |
| “Revised GAAP diluted EPS guidance range to $3.84 to $3.94 from $4.23 to $4.43” | ||||||||
| FY 2025revised | EPS (adj.) | $6.00–$6.20 | 2025-05-01 | $6.75 | +9.0% | ABOVE | guidance · result | |
| “Raised Adjusted EPS guidance range to $6.00 to $6.20 from $5.75 to $6.00” | ||||||||
| FY 2025revised | EPS | $4.23–$4.43 | 2025-05-01 | $1.39 | −65.6% | BELOW | guidance · result | |
| “Revised GAAP diluted EPS guidance range to $4.23 to $4.43 from $4.58 to $4.83” | ||||||||
| FY 2025 | EPS (adj.) | $5.75–$6.00 | 2025-02-12 | $6.75 | +12.8% | ABOVE | guidance · result | |
| “Adjusted EPS guidance range of $5.75 to $6.00” | ||||||||
| FY 2025 | EPS | $4.58–$4.83 | 2025-02-12 | $1.39 | −67.8% | BELOW | guidance · result | |
| “GAAP diluted EPS guidance range of $4.58 to $4.83” | ||||||||
| Q3 FY2024 | EPS (adj.) | $1.05–$1.10 | 2024-10-18 | $1.09 | 0.0% | IN LINE | guidance · result | |
| “Company provides preliminary guidance for third quarter 2024 GAAP diluted Earnings per Share (EPS) of $0.03 to $0.08 and Adjusted EPS of $1.05 to $1.10” | ||||||||
| Q3 FY2024 | EPS | $0.03–$0.08 | 2024-10-18 | $0.07 | 0.0% | IN LINE | guidance · result | |
| “Company provides preliminary guidance for third quarter 2024 GAAP diluted Earnings per Share (EPS) of $0.03 to $0.08 and Adjusted EPS of $1.05 to $1.10” | ||||||||
| FY 2024 | EPS (adj.) | $6.40–$6.65 | 2024-08-07 | — | — | — | PENDING | guidance |
| “Revised Adjusted EPS guidance to a range of $6.40 to $6.65 from at least $7.00” | ||||||||
| FY 2024 | EPS | $4.95–$5.20 | 2024-08-07 | — | — | — | PENDING | guidance |
| “Revised GAAP diluted EPS guidance to a range of $4.95 to $5.20 from at least $5.64” | ||||||||
Every figure above is read from the company’s own filings. “Guidance” links to the 8-K exhibit that issued the forecast; “result” links to the exhibit in which the company reported the outcome. Nothing here is an analyst estimate. How this is measured.